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TITLE OF CASE  
 
Voriconazole-induced periostitis in a patient with overlap syndromes 
 
AUTHORS OF CASE Please indicate corresponding author by *(after the author’s 
name) 
Keisho Hirota, Akihiro Yasoda*, Toshihito Fujii and Nobuya Inagaki 
SUMMARY Up to 150 words summarising the case presentation and outcome 
52-year-old woman with overlap syndrome and interstitial pneumonia underwent 
immunosuppressive therapy and she was suspected to suffer from pulmonary aspergillosis. Oral 
voriconazole was initiated, and rapid elevations of ALP were appeared after 4 weeks. After 2 
months, the patient presented diffuse pain in bilateral skeletal regions and bone scintigraphy 
revealed bilateral multiple areas of increased radiotracer uptake. We suspected the skeletal 
involvement as voriconazole-induced periostitis. Actually, the plasma fluoride level was 
increased. Voriconazole was replaced to itraconazole, and after 3 weeks, the patient stopped 
complaining of bone pain concomitant with the decrease in ALP. Voriconazole-induced 
periostitis is a rare condition but had previously been reported in solid organ or bone marrow 
transplant patients who received long-term voriconazole therapy. Our present case is distinctive 
for previous ones, because it was occurred in a patient with connective tissue disease and further 
with its rapid progression. 
BACKGROUND Why you think this case is important – why you decided to write it 
up 
Voriconazole is a triazole agent that contains 3 fluoride atoms 1. Although voriconazole is 
efficacious for the treatment of invasive aspergillosis and recommended by most international 
guidelines 2 3 4, it is recently reported to cause fluorosis that develops diffuse painful periostitis 5 6 
7 8 9 10 11 12. Here we report a case of voriconazole-induced periostitis in a patient with 
undifferentiated rheumatic diseases, or overlap syndrome. Voriconazole-induced periostitis was 
previously reported in solid organ or bone marrow transplant patients who received long-term 
voriconazole therapy. Recently, Gladue et al. reported a case of voriconazole-induced periostitis 
occurred in a patient with granulomatosis with polyangitis 13. Our present report would be the 
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next case of voriconazole-induced periostitis occurred in the course of connective tissue disease. 
Furthermore, our patient presented the earliest onset of the findings, to our best knowledge. 
CASE PRESENTATION Presenting features, medical/social/family history 
The case is a 52-year-old woman with a history of overlap syndrome, including systemic lupus 
erythematosus, systemic sclerosis, and dermatomyositis and interstitial pneumonia. She 
underwent immunosuppressive therapy including cyclosporine and betamethasone. She was 
admitted to our hospital for exacerbation of interstitial pneumonia and treated with 
cyclophosphamide pulse therapy. In the course of the treatment, CT scan of the chest showed a 
cavity in upper-right lung. Although aspergillus antigen and β-D-glucan tests were negative, 
clinical history and imaging findings were compatible with pulmonary aspergillosis. Oral 
voriconazole was initiated at the dose of 600 mg/day and persisted to maintain serum levels at 
about 3 μg/mL. Approximately after 4 weeks of the initiation of the voriconazole therapy, rapid 
elevations of ALP were appeared. After the 2-month therapy, the patient presented diffuse pain in 
bilateral shoulders, humeri, scapulae, and hypochondriac and femoral regions. After 4 months of 
the initiation of the therapy, bone scintigraphy was performed and revealed multiple areas of 
increased radiotracer uptake in bilateral scapulae, ribs, and cortex of femurs (figure 1). The bone 
metabolic markers were elevated; ALP, bone alkaline phosphatase (BAP), tartrate-resistant acid 
phosphatase (TRACP)-5b and pyridinoline cross-linked carboxyterminal telopeptide of type 1 
collagen (1CTP) were 1060 IU/L (normal 115-359 IU/L), 89.3 μg/L (normal 3.8-22.6 μg/L), 
857 mU/dL (120-420 mU/dL), and 14.0 ng/mL (normal < 5.5 ng/mL), respectively, but serum 
levels of calcium (9.4 mg/dL adjusted by serum albumin levels, normal 8.7-10.1 mg/dL) and 
phosphorus (3.5 mg/dL, normal 2.6-4.5 mg/dL), intact PTH (46 pg/mL, normal 10-65 pg/mL), 
PTHrP (< 1.1 pmol/L, within normal range), and 1,25-dehydroxy vitamin D3 (20-60 pg/mL) were 
within normal ranges. CT scan revealed periosteal reactions in some sites and exostoses in right 
scapula and left iliac bone (figure 2). MRI revealed high intensity areas on T2 weighed imaging 
in cortex of these regions and were compatible with periostitis. Bone biopsy was performed from 
exostosis of left iliac bone, and the pathological examination revealed increase of bone tissue with 
osteosclerosis. This was compatible with periostitis but not a specific finding of a distinct disease. 
Because the symptoms began after the initiation of voriconazole and the pattern of bilateral 
multiple periosteal involvements is compatible, we suspected the skeletal involvement as 
voriconazole-induced periostitis. As for the etiology of voriconazole-induced periostitis, fluorosis 
caused by excess intake of fluorides contained in voriconazole is supposed. So we measured the 
plasma fluoride level and revealed it to be 24.9 μmol/L (normal  1-4 μmol/L, toxic level > 15 
μmol/L).  













TREATMENT If relevant  
As the fluoride toxicity was suspected, voriconazole was discontinued and itraconazole was 
started at the dose of 200 mg/day.  
OUTCOME AND FOLLOW-UP   
After the discontinuance of voriconazole for 3 weeks, the patient stopped complaining of bone 
pain, and ALP decreased to 458 IU/L. Nevertheless, the plasma fluoride level still remained to be 
19.0 μmol/L. 
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DISCUSSION including very brief review of similar published cases (how many 
similar cases have been published?)  
Prolonged ingestion or inhalation of high levels of fluoride ion causes skeletal fluorosis. Fluoride 
ion is reported to stimulate osteoblasts and lead to osteosclerosis 14 15. Chronic toxicity of fluoride 
ion contributes to increase the poor-quality bone and painful calcification or ossification of 
tendon and ligament 16. The chemical and structural characters of fluoride ion resemble those of 
hydroxide, and the alteration of hydroxyapatite to fluoroapatite induces bone fragility 17. 
Voriconazole contains 3 fluoride atoms, which account for 16.3% by weight 2.  As oral 
bioavailability of fluoride was reported to be 96%, about 78 mg of fluoride was ingested each day 
in our case. The World Health Organization (WHO) states that there is a clear excess risk of 
skeletal fluorosis for a total fluoride intake of 14 mg/day and a suggestive evidence of an 
increased risk of bone effects at total intakes above 6 mg/day 18. Thus, our patient had taken total 
daily fluoride thirteen times more than the upper limit of the fluoride amount suggested by WHO. 
In addition, the plasma fluoride level still remained to be 19 μmol/L 3 weeks after the 
discontinuance of voriconazole, which is higher than those of general population. Fluoride is 
excreted in urine or accumulated in bone, and the plasma level of fluoride drops to the value of 
before intake in 24 hours 19. We think fluoride accumulation in bone caused extended release of 
fluoride from bone in our case. 
Voriconazole-induced periostitis is suspected to be caused by the accumulation of fluoride 8 9 11. 
Patients of voriconazole-induced periostitis develop diffuse pain in extremity and exhibit an 
elevation of alkaline phosphatase (ALP). These symptoms are reported to appear from 6 weeks to 
53 months after the initiation of voriconazole 5 6 7 8 9 10 11 12. Radiographic image reveals 
symmetric periosteal reaction and skeletal lesions consist of periosteal thickening, periosteal 
calcification, calcification of ligaments, and osteosclerosis predominantly in proximal long bones, 
ribs, scapulae and iliac bones. Bone scintigraphy exhibits multiple areas of increased radiotracer 
uptake corresponding to multifocal periosteal lesions 5 6 7 10 12. These symptoms are reversible 
and improve within a few weeks after discontinuation of voriconazole. In past, all cases of 
voriconazole-induced periostitis were reported to be occurred in transplant recipients 5 6 7 8 12 or 
patients with hematological disorders 9 11. Recently, Gladue et al. reported a case of voriconazole-
induced periostitis occurred in a patient with granulomatosis with polyangitis 13. Our present 
report would be the next case of voriconazole-induced periostitis occurred in the course of 
connective tissue disease. Furthermore, in our case, the elevation of ALP occurred 4 weeks after 
the initiation of voriconazole and the diffuse pain developed within 2 months. This is the earliest 
onset of the findings that have ever been reported. Drug-drug interactions or inflammatory 
processes on periosteum might be the pathogenesis of this condition 11. 
In conclusion, we reported a case of voriconazole-induced periostitis developed in a patient with 
connective tissue disease. As the skeletal symptoms are reversible and ameliorated after the 
discontinuance of voriconazole, physicians should be aware of it when patients taking 
voriconazole suffer diffuse bone pains. 
LEARNING POINTS/TAKE HOME MESSAGES 3 to 5 bullet points 
We must suspect voriconazole-induced periostitis for diffuse bone pain and increased ALP in a 
patient who is taking voriconazole. 
Voriconazole-induced periostitis is a reversible condition and the discontinuance of voriconazole 
ameliorates the symptoms. 
Voriconazole-induced periostitis can occur in patients suffering from collagen diseases. 
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Bone scintigraphy representing multiple areas of increased radiotracer uptake in bilateral 
scapulae, ribs, and cortex of femurs after 4 months of the initiation of voriconazole. 
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figure 2 
CT images showing exostoses in right scapula and left iliac bone (red arrows). 
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